What is the real market size of neurotechnology?
Every funding round, every investor, and who is really ahead in neurotech, in one document. Have a look ↓
Summary
The real market size of neurotechnology is about $17 billion globally today, with roughly $15–20 billion as the most defensible range for the core commercial industry.
The headline disagreement is less dramatic than it looks. Once broad neuroscience equipment, general medical imaging and speculative future BCI markets are stripped out, several independent estimates cluster tightly around $16–18 billion.
Neuromodulation is already the commercial center of the industry. At roughly $6.4 billion, it represents a large chunk of current neurotechnology revenue before neural diagnostics, recording systems, neuroprosthetics and specialized research tools are counted.
The bottom-up numbers support the top-down estimates. Medtronic, Boston Scientific, Inspire, LivaNova, NeuroPace and Neuronetics alone generate about $5 billion of directly observable neurotechnology revenue, making a total market in the high teens quite plausible.
The part of neurotechnology receiving the most attention is nowhere near the part making the most money. Implantable BCIs still involve fewer than 200 reported recipients worldwide, while established stimulation businesses already generate billions of dollars every year.
Investment has moved far ahead of commercialization. BCI companies have reportedly raised more than $1 billion during 2026 alone, even though most implantable systems remain in clinical studies rather than routine commercial use.
Treatment currently generates far more revenue than neural reading, but the distinction is starting to blur. Responsive stimulation, adaptive deep-brain stimulation and newer cortical interfaces increasingly combine sensing and treatment in the same system.
Neurotechnology also has several different growth speeds. Mature neuromodulation franchises tend to grow around the mid- to high-single digits, while younger specialist platforms can still produce growth in the teens or twenties.
Huge neurological-disease populations should not be confused with current market size. Eligibility, reimbursement, surgical capacity, trained clinicians and treatment infrastructure sharply reduce the number of patients who can actually receive many neurotechnology products today.
The market does not need a spectacular BCI breakthrough to become much larger. Existing neuromodulation could add billions through ordinary adoption and new indications, while BCIs and consumer neural interfaces remain the much less proven upside.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us
We keep an up-to-date report on neurotech. Have a look ↓
Sample pages from an earlier edition. The report has been updated with new data since.
Why are neurotechnology market estimates all over the place?
Neurotechnology is currently a roughly $17 billion market under the most useful commercial definition, but published estimates become wildly different once researchers start mixing neurotechnology with medical imaging, general neuroscience equipment and futuristic BCI opportunities.
The strange part is that the more comparable estimates actually agree quite well. Fortune Business Insights recently put the 2025 neurotechnology market at $17.73 billion. Precedence Research calculated $17.32 billion. Mordor Intelligence estimated $15.77 billion.
A range of roughly $16–18 billion therefore appears repeatedly when the subject is neurostimulation, neuroprosthetics, neurorehabilitation and technologies that directly interact with the nervous system.
The confusion starts when the perimeter changes. Broader neuroscience markets can exceed $50 billion because they include equipment such as imaging and research systems. Some BCI reports produce numbers far beyond what existing BCI companies could possibly be selling today.
Averaging all those estimates would give us a precise-looking number with very little meaning. We need to compare markets that are actually measuring the same thing.
| What is being measured? | Approximate recent size | How we should read it |
|---|---|---|
| Core neurotechnology | ~$16–18B | Best starting point |
| Fortune neurotechnology estimate | $17.73B | Broad commercial neurotechnology |
| Precedence neurotechnology estimate | $17.32B | Broad commercial neurotechnology |
| Mordor neurotechnology estimate | $15.77B | Broad commercial neurotechnology |
| Neuromodulation devices | $6.4B | Large established submarket |
| Broader neuroscience equipment | $50B+ | Includes many adjacent technologies |
| Experimental invasive BCI industry | Far below $1B in product sales | Still mostly clinical and pre-commercial |
If you want more recent data on this point, see the latest figures in our Neurotech report ↓.
What should actually count as neurotechnology?
For a useful market-size estimate, neurotechnology should cover products whose main job is to record, interpret or change activity in the nervous system.
Deep-brain stimulation clearly belongs. So do spinal-cord stimulators, vagus-nerve stimulators, EEG systems, cortical electrodes, responsive neurostimulation and brain-computer interfaces.
General MRI creates more trouble. Brain imaging plays a huge role in neuroscience, but Siemens Healthineers, GE HealthCare and Philips sell scanners across cardiology, oncology, orthopedics and many other fields. Counting the whole MRI market would make almost any neuroscience-related medical device part of neurotechnology.
The same issue appears with digital mental-health apps and rehabilitation robotics. A product can serve patients with neurological conditions without directly interacting with neural activity.
We therefore use a fairly strict perimeter: neuromodulation and neurostimulation, neural recording and diagnostics, neuroprosthetics, BCIs, plus specialized tools designed specifically to measure or manipulate the nervous system.
That gives us a category we can actually compare with company revenue.
These pages are excerpts from our report. See the rest ↓
Sample pages from an earlier edition. The report has been updated with new data since.
How big is the neurotechnology market today?
The best current estimate for the global neurotechnology market is about $17 billion, and we would treat roughly $15–20 billion as the realistic range.
Three independent market estimates land surprisingly close to each other. Fortune Business Insights recently valued the 2025 market at $17.73 billion and now estimates $19.19 billion for 2026. Precedence Research starts from $17.32 billion. Mordor Intelligence uses $15.77 billion for 2025 and $17.84 billion for 2026.
We would not pretend that the difference between $17.3 billion and $17.7 billion tells us anything important. These are modeled markets, and their definitions still differ.
What matters is the order of magnitude.
A $17 billion estimate also survives a bottom-up reality check. Grand View Research currently puts neuromodulation devices alone at $6.4 billion in 2025. Add neural diagnostics, specialized recording equipment, neuroprosthetics, research technologies and smaller stimulation categories, and a figure in the high teens becomes believable.
Going much below $15 billion becomes difficult to reconcile with reported company sales. Going far above $20 billion requires bringing in increasingly broad neuroscience categories.
If you want more recent data on this point, see the latest figures in our Neurotech report ↓.
Do actual neurotechnology companies really sell enough to support a $17 billion market?
Yes. A handful of established neurotechnology businesses already generate more than $5 billion a year, so a global market around $17 billion passes the most important commercial sanity check.
Medtronic reported $2.068 billion of neuromodulation revenue in its latest full fiscal year, up 7%. Boston Scientific generated $1.199 billion from neuromodulation in 2025.
LivaNova produced $592.8 million from neuromodulation. Inspire Medical Systems reached $912 million with its hypoglossal-nerve stimulation platform. NeuroPace reached exactly $100 million of annual revenue, while Neuronetics reported $149.2 million.
Those companies already take us above $5 billion even before adding Abbott, numerous smaller neurostimulation businesses, EEG manufacturers, research-equipment companies, neural-monitoring systems and private neurotech startups.
As seen above, Grand View Research independently estimates the entire neuromodulation-device category at $6.4 billion. The company-level numbers land in the same neighborhood, which gives us much more confidence than a market-report headline on its own.
| Company | Relevant neurotechnology business | Latest annual revenue |
|---|---|---|
| Medtronic | Neuromodulation | $2.068B |
| Boston Scientific | Neuromodulation | $1.199B |
| Inspire Medical Systems | Hypoglossal-nerve stimulation | $912M |
| LivaNova | Neuromodulation | $592.8M |
| Neuronetics | TMS and neurohealth | $149.2M |
| NeuroPace | Responsive neurostimulation | $100.0M |
| electroCore | Non-invasive nerve stimulation and related products | ~$32M |
| Nexstim | Navigated TMS | ~€11M |
Prefer verified numbers to headlines? Our report is here ↓
Sample pages from an earlier edition. The report has been updated with new data since.
Which part of neurotechnology makes the most money today?
Neuromodulation is currently the commercial engine of neurotechnology, accounting for roughly $6.4 billion before we even include every adjacent stimulation product.
This is where the neurotechnology story looks much more mature than the headlines suggest.
Spinal-cord stimulation is already used for chronic pain. Deep-brain stimulation treats disorders including Parkinson's disease and essential tremor. Sacral neuromodulation addresses bladder and bowel dysfunction. Vagus-nerve stimulation has been commercialized in epilepsy. NeuroPace uses responsive brain stimulation for drug-resistant epilepsy. Inspire has built a business approaching $1 billion in annual revenue around stimulation for obstructive sleep apnea.
The products may sound less futuristic than mind-controlled computers, but people are already being treated with them in large numbers and healthcare systems are already paying for them.
Grand View Research now expects the $6.4 billion neuromodulation-device market to reach about $7 billion this year and $13.9 billion by 2033.
That base is large enough that even ordinary growth adds serious dollars. If the segment broadly follows that trajectory, several billion dollars of new neurotechnology revenue could appear before invasive BCIs contribute very much at all.
How big is the brain-computer interface market in the real world?
Implantable brain-computer interfaces are still tiny as a commercial business today, with fewer than 200 people worldwide reported to have received a BCI implant.
That number tells us more about the current BCI market than a forecast claiming tens or hundreds of billions of dollars.
Recent Financial Times reporting counted fewer than 200 implanted people across the entire field. Neuralink, Synchron, Precision Neuroscience, Blackrock Neurotech, Paradromics, CorTec and other developers are making genuine technical and clinical progress, but most of that progress is still happening through studies rather than ordinary commercial deployment.
Precision Neuroscience has obtained FDA clearance for temporary use of its Layer 7 cortical interface. Synchron has implanted its endovascular system in human patients. Neuralink continues adding participants and expanding clinical work beyond its earliest implants. China is also pushing BCIs as a strategic industry.
These developments make BCIs one of the most interesting parts of neurotechnology right now. They still amount to a very small share of current industry revenue.
Non-invasive interfaces have reached more users because EEG devices can be sold without surgery. Companies such as EMOTIV, OpenBCI and Neurable already have commercial products. Yet no brain-interface platform has reached anything resembling the consumer scale of smartwatches, headphones or hearing devices.
For now, the BCI opportunity is vastly larger than the BCI business.
If you want more recent data on this point, see the latest figures in our Neurotech report ↓.
Want to know who is really ahead? Our report is here ↓
Sample pages from an earlier edition. The report has been updated with new data since.
Why are investors putting so much money into BCIs when the market is still tiny?
Investors are paying for the chance that BCIs become a major medical platform later, which explains why funding has raced far ahead of current revenue.
This gap has become even harder to miss lately.
BCI companies have raised more than $1 billion during 2026 alone, according to recent Financial Times reporting. Neuralink accounts for around $1.3 billion of cumulative funding, while Precision Neuroscience, Synchron, Paradromics and others have also raised substantial amounts.
Compare that with fewer than 200 implanted BCI patients worldwide.
Neuralink's $650 million financing in 2025 captured the difference especially well. Reports at the time put the company around a $9 billion pre-money valuation while Neuralink said five people were using its implant.
There is also a large public research layer underneath the private investment. The NIH BRAIN Initiative currently has a $429 million annual budget, up from $321 million in the previous fiscal year. That program supports tools, neural interfaces, research infrastructure and basic neuroscience rather than one commercial product.
The money flowing into BCIs therefore tells us plenty about expectations and very little about today's market size.
If high-bandwidth interfaces eventually restore speech, movement, vision or other lost functions at scale, the revenue could become enormous. Investors are trying to own part of that possibility before the customer base exists.
Is Neuralink already one of the biggest neurotechnology businesses?
Neuralink is one of neurotechnology's most valuable private companies, but companies such as Medtronic, Boston Scientific and Inspire are still vastly larger when we measure what customers actually buy.
Medtronic's neuromodulation operation recently generated more than $2 billion in a single year. Boston Scientific reached nearly $1.2 billion. Inspire reached $912 million.
Neuralink remains in clinical development.
That comparison explains much of the confusion around neurotechnology today. Public attention concentrates on the part of the industry with the smallest current commercial base.
A multibillion-dollar Neuralink valuation reflects expectations about what implanted neural interfaces might eventually become. Revenue measures what the market has already become.
Both numbers are useful, but they answer completely different questions.
How much of neurotechnology is already a real medical-device business?
A surprisingly large part of neurotechnology already behaves like a conventional medical-device industry, with hundreds of millions in sales, high gross margins and established reimbursement.
Inspire is one of the clearest examples. The company generated $912 million in 2025 revenue, up 14%, with an 85.4% gross margin. It also reported $51 million in operating income.
NeuroPace reached $100 million of revenue after growing 25%, with a 77.2% gross margin. Its core RNS system generated $81.7 million.
LivaNova's neuromodulation segment reached $592.8 million and grew 7%. Medtronic's much larger neuromodulation business also grew 7%.
Neuronetics reported $149.2 million after its Greenbrook acquisition. The headline growth rate was 99%, although adjusted pro-forma growth was a much more ordinary 15%. That distinction is useful because neurotechnology growth can look spectacular when acquisitions are mixed into the numbers.
The businesses that work commercially tend to have something very concrete in common: they solve a defined clinical problem, fit into an existing medical workflow and have a way to get paid.
A vague promise to “connect the brain to technology” is much harder to monetize.
We made a report out of all this. Take a look ↓
Sample pages from an earlier edition. The report has been updated with new data since.
Is neurotechnology mainly about treating the nervous system or reading it?
Treatment makes most of the money in neurotechnology today, while neural recording remains smaller and more fragmented.
The revenue concentration makes that fairly obvious. Medtronic, Boston Scientific, Inspire, LivaNova and NeuroPace all generate their relevant sales primarily by changing neural activity to treat a medical condition.
Recording technologies span EEG, intracranial monitoring, cortical electrodes, MEG, neural research tools and emerging BCIs. They are commercially real, but sales are divided among many suppliers and end markets.
The more interesting development these days is that reading and stimulation are starting to converge.
NeuroPace already detects abnormal brain activity and responds with stimulation. Newer cortical interfaces can both record and stimulate. Adaptive deep-brain stimulation is moving in the same direction, using the patient's neural activity to change how stimulation is delivered.
That could reshape the market because the device starts acting less like a fixed electrical implant and more like a system that continuously measures what the nervous system is doing.
The commercial center still sits with treatment. The technology is gradually moving toward systems that can sense and treat at the same time.
How fast is the neurotechnology market actually growing?
The core neurotechnology market is probably growing around high-single to low-double digits, with mature businesses growing more slowly than younger platforms.
Published forecasts vary a lot. Fortune Business Insights currently expects 7% annual growth through 2034. Mordor Intelligence projects 13.1%. Precedence Research is around 13%. Grand View Research forecasts 10.4% for neuromodulation devices.
The company results give us a useful reality check.
Medtronic's latest full-year neuromodulation sales rose 7%. Its most recent quarter still showed low-single-digit organic growth in neuromodulation. Boston Scientific's 2025 neuromodulation revenue increased from $1.106 billion to $1.199 billion, or about 8%. LivaNova grew 7%. Inspire grew 14%. NeuroPace grew 25%.
That looks like a market with several speeds.
The giant established franchises are generally growing in the mid- to high-single digits. Specialist companies with newer products can grow in the teens or twenties. BCIs can multiply patient numbers very quickly from a base so small that the percentage tells us almost nothing about market revenue.
A reasonable current assumption is therefore around 7–13% annual growth for the broader neurotechnology category rather than one spectacular industry-wide growth rate.
| Company or market | Latest growth measure | What we learn from it |
|---|---|---|
| Medtronic neuromodulation | +7% | Mature franchise |
| Boston Scientific neuromodulation | ~+8% | Mature franchise |
| LivaNova neuromodulation | +7% | Mature franchise |
| Inspire Medical Systems | +14% | Faster specialist growth |
| NeuroPace | +25% | Smaller platform scaling quickly |
| Neuronetics | +15% adjusted pro forma | Underlying growth below headline rate |
| Grand View neuromodulation forecast | +10.4% CAGR | Midpoint of current industry estimates |
| Broader neurotechnology forecasts | ~7–13% CAGR | Wide but plausible current range |
If you want more recent data on this point, see the latest figures in our Neurotech report ↓.
If this is useful, the full report goes much further. Have a look ↓
Sample pages from an earlier edition. The report has been updated with new data since.
Does the huge number of people with neurological disorders make neurotechnology a huge market?
No. Neurological disease creates a massive potential customer base, but only a small share of those patients currently qualify for, receive or can access a neurotechnology device.
This is where some long-term market estimates get too optimistic.
Parkinson's disease, epilepsy, depression, chronic pain, Alzheimer's disease, paralysis and other neurological conditions affect hundreds of millions of people collectively. It is tempting to multiply those populations by a hypothetical device price and call the result an addressable market.
Actual adoption works differently.
Deep-brain stimulation is used only for selected patients. Responsive neurostimulation targets specific forms of drug-resistant epilepsy. TMS requires repeated treatment sessions and specialized infrastructure. Implanted BCIs are still experimental. Even a successful commercial platform can run into shortages of trained physicians, surgical capacity and reimbursement coverage.
Inspire provides a useful example. The company has already built a business approaching $1 billion, yet management has repeatedly had to work on expanding physician and treatment-center capacity as demand grows.
A disease population tells us where neurotechnology could eventually go.
Today's market depends on how many people can actually receive a product, whether the treatment works well enough, whether clinicians can deliver it and whether someone pays the bill.
What could make neurotechnology much bigger over the next five years?
Neurotechnology can become much larger even without a sudden Neuralink-style breakthrough, because the existing neuromodulation market already has enough scale to add billions through ordinary adoption.
Grand View Research estimates that neuromodulation alone could grow from $6.4 billion in 2025 to $13.9 billion by 2033. That would add roughly $7.5 billion to one existing segment.
New indications can expand the market further. A stimulation platform that starts with epilepsy, chronic pain or Parkinson's disease becomes much more valuable if clinical evidence supports additional disorders.
Closed-loop systems could also push spending higher. NeuroPace already shows how recording neural activity and adjusting stimulation can become one product. Adaptive DBS is moving along the same path.
BCIs would create a very different growth curve if clinical trials turn into repeatable commercial treatment. The numbers required to matter are easy to see. A few hundred implanted people barely move a $17 billion industry. Tens of thousands of patients paying for expensive systems, surgery and follow-up care would.
Consumer neurotechnology is the biggest wildcard. Brain sensing built into headphones, wearables or other everyday devices could expand the addressable population far beyond specialist hospitals, but nobody has yet shown a consumer neural product with mass-market staying power.
The next five years therefore do not require science fiction to make neurotechnology significantly larger. Existing medical products already have room to expand, while BCIs provide the upside case.
Want the whole picture? Check our report ↓
Sample pages from an earlier edition. The report has been updated with new data since.
So what is the real market size of neurotechnology?
The neurotechnology market is currently about $17 billion globally, with roughly $15–20 billion as the range we would actually use for the core commercial industry.
That conclusion holds up better after looking beyond market reports alone.
Three recent independent estimates cluster around $16–18 billion. Neuromodulation already accounts for about $6.4 billion. Medtronic, Boston Scientific, Inspire, LivaNova, Neuronetics and NeuroPace together provide billions of dollars of directly observable neurotechnology sales. Adding the rest of neuromodulation, neural diagnostics, recording systems, neuroprosthetics and specialized research technologies comfortably brings the market into the high teens.
Figures above that can still be legitimate if the question changes. A broader neuroscience market can include imaging and general research equipment. Future BCI opportunity can run far beyond today's sales. Neither should quietly be presented as current core neurotechnology revenue.
The biggest misconception around this market comes from attention rather than arithmetic. The most visible companies are developing implants that still reach fewer than 200 people worldwide, while less glamorous neurostimulation products already generate billions of dollars every year.
So $17 billion is the number we would use today.
The interesting part now is how quickly the commercial market begins to resemble the much bigger neurotechnology story investors are already pricing in.
If you want more recent data on this point, see the latest figures in our Neurotech report ↓.
From our neurotech report, updated regularly. Have a look ↓
Sample pages from an earlier edition. The report has been updated with new data since.
Our methodology
There is no single, universally accepted number for the neurotechnology market. We therefore separated core neurotechnology from broader neuroscience equipment, general medical imaging and future BCI opportunity before comparing the published market estimates.
We used a fairly strict commercial definition: neuromodulation and neurostimulation, neural recording and diagnostics, neuroprosthetics, BCIs, and specialized technologies designed specifically to measure or manipulate the nervous system. General-purpose MRI, broad digital-health products and rehabilitation technologies were not automatically counted simply because they can be used in neurological care.
Market-research estimates were treated as top-down reference points rather than definitive answers. We compared recent estimates from Fortune Business Insights, Precedence Research, Mordor Intelligence, and the Grand View Research neuromodulation market to see where independently produced estimates converged.
We then tested that top-down range against observable company revenue. Primary financial sources included Medtronic's FY2026 SEC filing, Boston Scientific's 2025 Form 10-K, Inspire Medical Systems' FY2025 results, LivaNova's 2025 Annual Report, NeuroPace's FY2025 results, and Neuronetics' FY2025 results.
For smaller public businesses, we also used electroCore's FY2025 results and Nexstim's 2025 financial statements. These company figures are useful because they show whether the scale suggested by market reports is compatible with revenue that can actually be observed.
We kept current revenue, investment, valuation, clinical deployment and research funding separate. For the BCI section, key sources included Financial Times reporting on implanted BCI patients and investment, Neuralink's Series E announcement, the NIH BRAIN Initiative budget, and the Synchron INTENT study record.
Regulatory progress was checked separately from commercial adoption. Relevant sources included the FDA record for Precision Neuroscience's Layer 7-T cortical electrode, Precision Neuroscience's clearance announcement, and the FDA guidance for implanted BCI devices.
The final range comes from convergence rather than averaging every published number. We gave the most weight to estimates with comparable definitions, segment-level market data that could be cross-checked, reported company revenues and current commercialization evidence. Valuations, disease populations and long-term addressable-market projections were used to understand future potential, not to inflate today's market size.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us